Clinical experience with insulin glargine in type 1 diabetes

Diabetes Technology and Therapeutics

Volumn 12, Issue 11, 2010, Pages 835-846

  Garg, Satish ^a   Moser, Emily ^a   Dain, Marie Paule ^b   Rodionova, Anastasia ^a  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

BEDTIME DOSAGE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; DIABETES MELLITUS, TYPE 1; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN, LONG-ACTING; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78649364069     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0135     Document Type: Review

References (75)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
2. Hirsch IB: Insulin analogues. N Engl J Med 2005;352: 174-183.
3. Coppolino R, Coppolino S, Villari V: Study of the aggregation of insulin glargine by light scattering. J Pharm Sci 2006;95:1029-1034.
4. Ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW: Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. Diabetes Care 2000;23:1467-1471.
5. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
6. Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU: Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007;29:1607-1619.
7. Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H: Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009;180:385-397.
8. Monami M, Marchionni N, Mannucci E: Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009;11:372-378.
9. Hermansen K, Heller S, Andersen M, Russell-Jones D: Insulin detemir reduces hypoglycemic risk at comparable HbA1c values compared to NPH insulin in patients with Type 1 diabetes [abstract 2059-PO]. Diabetes 2009;58(Suppl 1):A529-A530.
10. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB: Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003;26: 1490-1496.
11. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Perriello G, Bolli GB: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given mealtime lispro insulin. Diabet Med 2004;21:1213-1220.
12. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-1671.
13. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-643.
14. Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A: A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005;21:545-553.
15. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ: Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes\the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 2007;77:215-222.
16. Fulcher GR, Gilbert RE, Yue DK: Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 2005;35:536-542.
17. Bolli GB, Songini M, Trovati M, Del Prato S, Ghirlanda G, Cordera R, Trevisan R, Riccardi G, Noacco C: Lower fasting blood glucose, glucose variability and nocturnal hypogly-caemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes. Nutr Metab Cardiovasc Dis 2009;19:571-579.
18. Hershon KS, Blevins TC, Mayo CA, Rosskamp R: Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract 2004;10:10-17.
19. Ashwell SG, Gebbie J, Home PD: Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart. Diabet Med 2006;23:879-886.
20. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, Vogelsang DA, Smith SA, Rizza RA, Isley WL: Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005;28:10-14.
21. Carroll MF, Schade DS: The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005;11: 55-64.
22. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990;33:52-59.
23. Koivisto VA, Yki-Järvinen H, Helve E, Karonen SL, Pelk-onen R: Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986;35:78-82.
24. Kobayashi K, Amemiya S, Sawanobori E, Higashida K, Ishihara T, Kobayashi K, Kato K, Nakazawa S: Role of IGF binding protein-1 in the dawn phenomenon and glycemic control in children and adolescents with IDDM. Diabetes Care 1997;20:1442-1447.
25. Yagasaki H, Kobayashi K, Saitou T, Nagamine K, Mitsui Y, Mochizuki M, Kobayashi K, Cho H, Ohyama K, Amemiya S, Nakazawa S: Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: differences in the dawn phenomenon between insulin regimens. Exp Clin Endocrinol Diabetes 2010;118:195-199.
26. Heise T, Nosek L, Ronn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53: 1614-1620.
27. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49: 2142-2148.
28. Ashwell SG, Gebbie J, Home PD: Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet Med 2006;23: 46-52.
29. Hamann A, Matthaei S, Rosak C, Silvestre L: A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003;26:1738-1744.
30. Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD: Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 2006;23:285-292.
31. Bragd J, Adamson U, Lins PE, Von Dobeln A, Oskarsson P: Basal insulin substitution with glargine or CSII in adult type I diabetes patients\a randomized controlled trial [abstract 229-OR]. Diabetes 2009;58:A60.
32. Lepore G, Dodesini AR, Nosari I, Trevisan R: Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003;26:1321-1322.
33. Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005;28:533-538.
34. Bode BW, Steed RD, Schleusener DS, Strange P: Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract 2005; 11:157-164.
35. Maran A, Crazzolara D, Nicoletti M, Costa S, dal Pos M, Tiengo A, Avogaro A, Bruttomesso D: A randomized crossover study to compare continuous subcutaneous insulin infusion (CSII) with multiple daily injection (MDI) in type 1 diabetic patients previously treated with CSII [abstract 902]. Diabetologia 2005;48:A328.
36. Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A: In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet Med 2008;25:326-332.
37. Bolli GB, Kerr D, Thomas R, Torlone E, Sola-Gazagnes A, Vitacolonna E, Selam JL, Home PD: Comparison of a multiple daily insulin injection regimen (basal once-daily glar-gine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009;32: 1170-1176.
38. Grimaldi A, Vialettes B, Blayo A, Brun JM, Halimi S: Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab 2007;33:121-128.
39. rd: From randomized trials to registry studies: translating data into clinical information. Nat Clin Pract Cardiovasc Med 2008;5:613-620.
40. Hannan EL: Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-217.
41. Cramer JA, Pugh MJ: The influence of insulin use on gly-cemic control: how well do adults follow prescriptions for insulin? Diabetes Care 2005;28:78-83.
42. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL: Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data. Clin Ther 2006;28:1712-1725; discussion 1710-1711.
43. Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342: 1878-1886.
44. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-1892.
45. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M: The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin 2004;20:1703-1710.
46. Albright ES, Desmond R, Bell DS: Efficacy of conversion from bedtime NPH insulin injection to once-or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004;27:632-633.
47. Conget I, Storms F, Rodriguez J, Leperlier C, Davies M, Gomis R: Changing from prior premix insulin regimen to insulin glargine in patients with type 1 diabetes: results from the AT.LANTUS trial [abstract 83]. Diabetologia 2004;47:A33.
48. Raz I, Storms F, Rodriguez J, Bianchi-Biscay M, Davies M, Gomis R: Changing from once-or twice-daily basal insulin to once-daily insulin glargine in adult type 1 diabetes: results from the AT.LANTUS trial [abstract 848]. Diabetologia 2004;47:A306.
49. Dabrowski M, Nowakowski A: [Long-term efficacy of insulin glargine in adult type 1 diabetic patients not controlled on previous treatment.] Diabetologia Doswiadczalna i Kliniczna 2007;7:178-183.
50. Schreiber SA, Russmann A: Long-term efficacy of insulin glargine therapy with an educational programme in type 1 diabetes patients in clinical practice. Curr Med Res Opin 2007;23:3131-3136.
51. Maia FF, Melo FJ, Araujo IM, Araujo LR: [Switching of NPH insulin to glargine therapy in a cohort of diabetic patients: observational study]. Arq Bras Endocrinol Metabol 2007;51:426-430.
52. Kanazawa Y, Igarashi Y, Komiya K, Sakurai Y, Shimizu T, Fujitani Y, Tanaka Y, Watada H, Kawamori R, Hirose T: Long-term efficacy of insulin glargine after switching from NPH insulin as intensive replacement of basal insulin in Japanese diabetes mellitus. Comparison of efficacy between type 1 and type 2 diabetes (JUN-LAN Study 1.2). Endocr J 2007;54:975-983.
53. Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P: The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin 2007; 23(Suppl):S33-S39. (Pubitemid 46456919)
54. Daikeler R, Hogy B, Donaubauer B: [Effects of an intensified insulin therapy (ICT) with insulin glargine and insulin glu-lisine on patient reported outcomes (PRO) in diabetes mel-litus.] Diabetologie und Stoffwechsel 2007;2:308-314.
55. Schreiber S, Ferlinz K, Donaubauer B: Efficacy of combining insulin glulisine with basal insulin glargine in patients with type I and type 2 diabetes previously on premix insulin therapy [abstract 0992]. Diabetologia 2007;50(Suppl 1): S410-S411.
56. Schreiber S, Landgraf W, Bohler S: [Efficacy and tolerability of insulin glargine in ICT.] Diabetes, Stoffwechsel und Herz 2009;8:91-98.
57. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P: Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis. Cardiovasc Diabetol 2009;8:9.
58. Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P: Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study. Cardiovasc Diabetol 2009;8:3.
59. Johansen OE, Vanberg PJ, Kilhovd BK, Jorgensen AP: Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypo-glycemia. Vasc Health Risk Manag 2009;5:121-128.
60. Ruhnau K: Introduction of insulin glulisine in combination with insulin glargine to basal-bolus therapy improves metabolic control in patients with type 1 diabetes in everyday clinical practice [abstract 2071-PO]. Diabetes 2006;55(Suppl 1):A479.
61. Winkler G, Martinka E, Genestin E, Paulbouter K: API-WATCH\interim results of a meta-analysis of pan-European real-life investigations with insulin glulisine to control A1c in type 1 diabetes [abstract 2006-PO]. Diabetes Care 2009;58:A514-A515.
62. Chase HP, Arslanian S, White NH, Tamborlane WV: Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 2008;153: 547-553.
63. Frohlich-Reiterer EE, Ong KK, Regan F, Salzano G, Acerini CL, Dunger DB: A randomized cross-over trial to identify the optimal use of insulin glargine in prepubertal children using a three-times daily insulin regimen. Diabet Med 2007;24:1406-1411.
64. Murphy NP, Keane SM, Ong KK, Ford-Adams M, Edge JA, Acerini CL, Dunger DB: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003;26:799-804.
65. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K: Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes. Diabetes Care 2001;24:2005-2006.
66. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K: Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15:369-376.
67. Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA: A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics 2008;121:e466-e472.
68. Mianowska B, Szadkowska A, Czerniawska E, Pietrzak I, Bodalski J: [Insulin glargine improves fasting blood glucose levels in prepubertal children with unsatisfactorily controlled type 1 diabetes]. Pediatr Endocrinol Diabetes Metab 2007;13:189-193.
69. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD: Treatment satisfaction and quality of life with insulin glar-gine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008;31:1112-1117.
70. Witthaus E, Stewart J, Bradley C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet Med 2001;18:619-625.
71. Blonde L, Dey J, Testa MA, Guthrie RD: Defining and measuring quality of diabetes care. Prim Care 1999;26:841-855.
72. Finkel ML: The importance of measuring patient satisfaction. Empl Benefits J 1997;22:12-15.
73. Biderman A, Noff E, Harris SB, Friedman N, Levy A: Treatment satisfaction of diabetic patients: what are the contributing factors? Fam Pract 2009;26:102-108.
74. Samann A, Muhlhauser I, Bender R, Kloos C, Muller UA: Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study. Diabetologia 2005;48:1965-1970.
75. Danne T: Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007;29(Suppl D):S145-S152.